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Inguinal hernia repair is a clean surgical procedure and surgical site infection (SSI) rate is
generally below 2%. Antibiotic prophylaxis is not routinely recommended, but it may be a
good choice for institutions with high rates of wound infection (>5%). Typical prophylaxis
is the intravenous application of first or second-generation cephalosporins before the skin
incision. However, SSI rate remains more than 2% in many centers in spite of intravenous
antibiotic prophylaxis. Even a 1% SSI rate may be unacceptable for the surgeons who
specifically deal with hernia surgery. A hernia center targets to be a center of excellence
not only in respect of recurrence rate but also for other postoperative outcomes, there-
fore a further measure is required for an excellent result regarding infection control.Topical
gentamycin application in combination with preoperative single-dose intravenous antibiotic
may be a useful to obtain this perfect outcome. Data about this subject are not complete
and high-grade evidence has not been cumulated yet. Prospective randomized controlled
trials can make our knowledge more solid about this subject and help the surgeons who
seek perfect outcome regarding infection control in inguinal hernia surgery.
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INTRODUCTION
Surgical site infection (SSI) is an annoying complication for
both surgeons and patients. SSI consumes extra time and money,
accounting for 20% of all healthcare-associated infections (1). SSI
develops in 5% of patients (2). SSIs can increase in-hospital time
and repetitive admissions to outpatient clinics. When a prosthetic
material is used, an extra problem may arise: necessary extraction
of the prosthesis because of a deep and resistant infection.
Inguinal hernia repair is a clean surgical procedure and the
SSI rate is generally below 2%; however, every institution has its
own infection figure and many of them cannot produce that low
rate. General hospitals, especially centers who receive every kind
of surgical case, including trauma and contaminated cases, may
have SSI rates >5% (3–5). Antibiotic prophylaxis, not routinely
recommended for inguinal hernia repair, may be a good choice for
institutions with high rates of wound infection (>5%) (6).
Typical antibiotic prophylaxis for an inguinal hernia repair
is the intravenous application of first- or second-generation
cephalosporins before skin incision (7, 8). It is possible to lower
the SSI rate with this prophylaxis; however, SSI rates remain above
2% in many centers despite intravenous antibiotic prophylaxis.
On the other hand, even a 1% SSI rate may be unacceptable for
surgeons who specifically deal with hernia surgery. A hernia center
aims to be a center of excellence, not only in terms of recurrence
rate but also for other postoperative outcomes (9); therefore, a
further measure is required for excellent infection control.
TOPICAL ANTIBIOTICS IN GENERAL
Topical antibiotics have been employed for the treatment of
infected wounds. Some antimicrobial agents have also been used
topically to reduce SSI rates. Topical antibiotic application has
many potential advantages over systematic use, though some spe-
cific disadvantages also exist (10). The clinical benefits of topical
antibiotic prophylaxis have not been extensively documented for
general surgical cases.
Commonly used antibiotics for topical prophylaxis are
cephalosporins, aminoglycosides, glycopeptides, chlorampheni-
col, and bacitracin (10); the doses, delivery methods, and phar-
macological profiles vary.
The benefits of topical antibiotic prophylaxis with various
agents have been documented for multiple surgical disciplines,
including ophthalmic, orthopedic, neurological, urological, and
general surgeries (11–16); however, the evidence for inguinal her-
nia repair with mesh is limited, as recent PubMed and Google
Scholar searches found only four controlled clinical studies
(5, 17–19).
The first clinical study to examine the merit of topical antibiotic
prophylaxis in inguinal hernia repairs was published in 1967 (20),
carried out in a hernia-specific institution in Canada, Shouldice
Hospital, by Ernest Ryan. He compared test group patients who
received topical penicillin solution to controls with no antibiotic
prophylaxis. The test group developed a 0.15% wound infection
rate whereas the control series had a 1.54% infection rate. Ryan
was the first believer of the concept that “all significant infections
in clean surgical wounds start during the time the wound is open
at operation.” He injected penicillin solution deep to the exter-
nal oblique aponeurosis after it was closed and the remainder was
injected on or into the more superficial tissues.
John Nicholls also used an antibiotic solution, made using
penicillin powder, into the deep and superficial tissues during
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the wound closure of inguinal hernia repairs after he read Ryan’s
article (21). He did not observe any local or systematic reaction
to penicillin, and recorded 3 wound infections out of a total of
136 patients (2.2%). His wound infection rate is higher than
Ryan obtained in Shouldice Hospital, possibly because of type
of his institution, which was a general hospital in Seychelles. He
also mentioned that only one of his three infections appeared
to have arisen spontaneously, the other two being attributable to
hematoma due to inadequate hemostasis.
Andersen and colleagues published their experience with topi-
cal ampicillin application in patients that underwent McVay repair
for inguinal hernias in 1980 (17). They delivered 1 g of ampicillin
powder into the subfascial layers in the test group and recorded a
3.7% wound infection rate, whereas the wound infection rate was
4.0% in the control group. They concluded that topical ampicillin
application had no effect.
Lazorthes et al., in 1992, published their controlled clinical
studies on local antibiotic prophylaxis in inguinal hernia repair
(18). Patients who received 750 mg of cefamandole directly into
the wound with local anesthesia developed no SSI, compared with
a 4.3% wound infection rate in patients who were not given local
prophylaxis. The costs of the antibiotics used were 10 times less
than the cost of the treatment of wound infections in the control
group.
GENTAMYCIN IN HERNIA REPAIR WITH MESH
As mesh repairs became the procedure of choice in most centers,
intravenous antibiotic prophylaxis gained popularity in inguinal
hernia repair but topical antibiotic use for SSI prophylaxis did
not. In 2004, the journal Hernia published a letter from Profes-
sor Maximo Deysine, MD, FACS (1931–2009) entitled,“Post mesh
herniorrhaphy infection control:Are we doing all we can?”(22). He
wrote that the postherniorrhaphy infection rate remained at unac-
ceptable levels for the last 30 years, whereas orthopedic surgeons,
as a group who utilized prosthetic devices judiciously, decreased
their infection rate from 10 to 1%. He continued: “A disturbing
fact is that 2–4% infection rate is expected and accepted by most
surgeons as a normal outcome of a ‘clean’ procedure. This attitude
is similar to that existing in the early 1800s when a 98% plus infec-
tion rate was considered ‘normal’ for elective surgery. Later on, the
discoveries and recommendations by Pasteur and Lister, departing
drastically from what was considered customary, originated a new
era in infection control. Their capacity for philosophical change
is needed today in the field of herniorrhaphy because we accept,
without resistance, figures that represent a very large number of
infected patients.”
Deysine was the author of the article entitled, “Pathophysi-
ology, prevention, and management of prosthetic infections in
hernia surgery” published in the “Groin Hernia Surgery” issue of
the classical series of the Surgical Clinics of North America in 1998
(23). Upon starting at a hernia clinic in 1981, he was faced with
five almost-consecutive infections in 1982 that prompted the team
to utilize prophylactic intravenous antibiotics (1 g first-generation
cephalosporin 30 min before surgery). Following an empirical sug-
gestion from Dr. Wesley Alexander, they started to use a wound
irrigation solution of 80 mg gentamycin and 250 mg saline as part
of a prospective strict surgical protocol. Deysine reported their
results in detail in 2006 and mentioned no SSI in 23 years after
a strict protocol for prevention of infection, including topical
gentamycin use (24).
As a surgeon who has a specific interest in hernia surgery,
this was my first real notice regarding topical gentamycin use
in hernia repairs with mesh. I kept reading Deysine’s paper
and refreshed my knowledge about gentamycin: it is an amino-
sugar linked by a glycosidic bond to a central aminocyclitol
ring. It causes a concentration-dependent bacterial killing that
is independent of the inoculum’s size, by first diffusing passively
across the bacterial pores’ outer membrane and then transvers-
ing the membrane by an energy-dependent system. Once in the
cytoplasm, gentamycin binds the 30S ribosomal subunit, which
leads to faulty reading of mRNA codons, i.e., the wrong amino
acids are incorporated into bacterial proteins. The gentamycin
killing effect is concentration-dependent and is followed by a
bacteriostatic effect. Other killing mechanisms, like electrostatic
interaction, have been postulated to explain the rapidity of its
lethal effect. Although it is most effective against Gram-negative
bacteria, gentamycin also has killing activity against staphylo-
cocci, including both S. aureus and S. epidermidis. The empir-
ical choice of a highly concentrated gentamycin solution may
explain our results because, at the concentration used, gentamycin
would be bactericidal and not bacteriostatic. Most important,
gentamycin shows antimicrobial synergy when used in combina-
tion with B-Lactams; thus our preoperative intravenous injection
of Cefazolin may have contributed to successful bacterial killing
whereupon both activity curves are combined. In other words,
B-Lactams seem to increase the antimicrobial effect potential of
gentamycin.
In fact, the first paper about topical gentamycin prophylaxis
in the prosthetic repair of hernias was published by Musella and
colleagues in 2001 (19). In this prospective randomized study,
absorbable collagen tampons treated with gentamycin were placed
in front of polypropylene mesh. The SSI rate was significantly
lower in the test group compared to the control group (0.3 vs.
2.0%). The authors stated that collagen causes faster coagulation,
so the occurrence of seroma and hematoma that could favor bacte-
rial proliferation may be reduced. Use of topical gentamycin allows
use of a concentration that is much higher than its systemic injec-
tion. The blood concentration of antibiotic remains low, reducing
ototoxicity and nephrotoxicity, while the local drug concentrations
are kept for at least 48 h (25); in this way, resistance to antibiotics
caused by low drug dosage is avoided.
Further evidence regarding gentamycin use was published by
the Aachen group, which has great experience in hernia surgery
and meshes. They have first shown that an antibiotic surface
modification of polyvinylidene fluoride (PVDF) mesh samples
is feasible with gentamycin with no cytotoxicity (26). Afterward,
it was presented that a surface modification of PVDF mesh sam-
ples using plasma-induced graft polymerization of acrylic acid
and supplementation of gentamycin is able to improve collagen
type I/III ratio, scar quality, and mesh integration (27). Later, they
showed a dose-dependent effect of gentamycin on MMP-2 expres-
sion and tissue integration in a transgenic mouse model (28). The
reduced MMP-2 protein expression and transcription after mesh
coating with 8µg/mg gentamycin, together with the improved
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collagen type I/III, hint at advanced tissue integration, even in
the long term. The next paper from the same group revealed
that gentamycin-supplemented PVDF mesh materials enhance tis-
sue integration due to transcriptionally reduced MMP-2 protein
expression (29). Their most recent study compared plain and mod-
ified gentamycin-supplemented PVDF meshes and shown that
serum concentrations of antibiotic display a peak value 1 h postop-
eratively and decline within the next day. The total size of the gran-
uloma was significantly smaller in the gentamycin group compared
to the control group. Except for a short period of increased expres-
sion of CD68 in the gentamycin group after 7 days, no further
difference was found in cellular immune response. The collagen
type I/III ratio was constant in the two mesh types without signifi-
cant differences between mesh materials. A significantly decreased
foreign body granuloma formation, compared to the pure PVDF
mesh group, was found. In vitro analysis showed efficient antibi-
otic effects of the gentamycin supplementation compared to the
pure PVDF mesh (30).
Obviously, all five studies from the Aachen group are experi-
mental rat studies, which do not examine the effects of gentamycin
application on clinical SSI rates; however, they provide important
data about the potential clinical benefits of topical gentamycin use
in inguinal hernia repair with prosthetic materials. These find-
ings may be relevant to the best outcome after mesh repair of
abdominal wall hernias.
Like other aminoglycosides, gentamycin is not accepted or suit-
able for a single-agent prophylaxis in surgical procedures (8); how-
ever, gentamycin is used in combination with cefazolin or metron-
idazole in some centers (31, 32). Nevertheless, most reports about
intravenous gentamycin prophylaxis are released from developing
and underdeveloped countries (32, 33) and/or for pediatric pop-
ulations (34, 35). A very recent study from Iran that examined the
adherence to American Society of Health System Pharmacists Sur-
gical Antibiotic Prophylaxis Guidelines reported that gentamycin
is one of the antibiotics most frequently used inappropriately for
intravenous SSI prophylaxis (31).
A recent randomized study from Nigeria, carried out in a pedi-
atric population, showed that single-dose intravenous gentamycin
prophylaxis can obtain a virtually zero percent SSI rate, whereas
the control group developed a 4.8% wound infection rate (Level of
Evidence 2B) (35). Finally, in 2009, Praveen and Rohaizak, from a
university hospital in Malaysia, reported that locally applied gen-
tamycin (irrigation solution included 160 mg gentamycin diluted
in 250 ml saline) is equivalent to intravenous gentamycin (injec-
tion solution included 240 mg gentamycin diluted in 10 ml saline)
in preventing SSI in inguinal hernia repair (5) (Table 1). However,
the infection rate in both groups was almost 7%, which is not
acceptable for this era. They call attention to the responsibility of
hematoma formation for the development of wound infection, as
Nicholls complained about three decades ago (21).
In fact, preventing hematoma formation reduces wound infec-
tion rate in many kinds of surgical procedures (36–39). Sur-
gical experience and measures for good hemostasis can lower
hematoma and subsequent infection rates, but a proper antibi-
otic prophylaxis may still be the key for best outcome after elective
hernia repairs. As mentioned earlier in this paper, a one or two
percent SSI rate can be deemed as acceptable in general, but every
Table 1 | A summary of data regarding topical gentamycine for SSI
prophylaxis in inguinal hernia repairs.
Author Year Article type Benefit Level of evidence
Musella 2001 Prospective randomized
clinical study
Yes 1B
Deysine 2004 Personal experience Yes 5 (Expert opinion)
Junge 2005 Experimental animal study Yes –
Deysine 2006 Retrospective clinical study Yes 4 (Case series)
Praven 2009 Prospective randomized
clinical study
Yes 1B
surgeon, especially one who has a special interest to one particular
field of surgery, really does not like, even hates, facing a wound
infection after an elective procedure in his specific interest area.
Therefore, as in the aphorism, “the perfect is the enemy of the
good,” a perfect antibiotic prophylaxis with intravenous single-
dose first-generation cephalosporin and topical gentamycin may
be the way to the very best outcome, regarding infection control
in elective inguinal hernia repair.
SUMMARY
Elective inguinal repair is a clean surgical procedure that has a
<2% SSI rate. Proper intravenous antibiotic prophylaxis provides
that low infection rate in many institutions; however, it is possible
to almost eliminate wound infection following elective inguinal
repair by using topical gentamycin application in combination
with preoperative single-dose intravenous antibiotic. Data about
this subject are not complete and high-grade evidence has not
been collected yet. Prospective randomized controlled trials can
solidify our knowledge about this subject and help surgeons who
seek perfect SSI outcomes in inguinal hernia surgery.
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